Galapagos to Acquire Inpharmatica for as Much as $25.4M | GenomeWeb
NEW YORK (GenomeWeb News) — Galapagos today said it plans to acquire Inpharmatica, a UK-based drug discovery database company in a stock deal that potentially worth €19.1 million ($25.4 million).
 
Galapagos said it estimates that Inpharmatica’s ongoing business is worth €6.5 million, the company has €6 million for the cash, and has a potential to earn around €6.6 million in milestones.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.